
Pharmacogenomics Market by Technology (DNA Sequencing, Electrophoresis, Mass Spectrometry), Application (Drug Discovery, Neurology, Oncology) - Global Forecast 2024-2030
Description
Pharmacogenomics Market by Technology (DNA Sequencing, Electrophoresis, Mass Spectrometry), Application (Drug Discovery, Neurology, Oncology) - Global Forecast 2024-2030
The Pharmacogenomics Market size was estimated at USD 8.48 billion in 2023 and expected to reach USD 9.10 billion in 2024, at a CAGR 5.97% to reach USD 12.73 billion by 2030.
Global Pharmacogenomics Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Pharmacogenomics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmacogenomics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Pharmacogenomics Market, highlighting leading vendors and their innovative profiles. These include Admera Health, Agena Biosciences Inc., BiogeniQ Inc., CENTOGENE N.V., Coriell Life Sciences, Dynamic DNA Laboratorie, Empire Genomics, Illunima Inc., Myriad Genetics Inc., OneOme LLC, Personalis Inc., Phamatech Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., and ViennaLab Diagnostics GmbH.
Market Segmentation & Coverage
This research report categorizes the Pharmacogenomics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Technology
DNA Sequencing
Electrophoresis
Mass Spectrometry
Microarray
Polymerase Chain Reaction
Application
Drug Discovery
Neurology
Oncology
Pain Management
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Pharmacogenomics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmacogenomics Market?
3. What are the technology trends and regulatory frameworks in the Pharmacogenomics Market?
4. What is the market share of the leading vendors in the Pharmacogenomics Market?
5. Which modes and strategic moves are suitable for entering the Pharmacogenomics Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
192 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Pharmacogenomics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidences of chronic diseases and demand for precision medicine
- 5.1.1.2. Increasing investments for healthcare infrastructures
- 5.1.1.3. Technological advancements associated with molecular diagnostics procedure
- 5.1.2. Restraints
- 5.1.2.1. High costs associated with research and development proficiencies
- 5.1.3. Opportunities
- 5.1.3.1. Emerging trend of personalized medicines
- 5.1.3.2. Rising R&D activities to improve pharmacogenomics
- 5.1.4. Challenges
- 5.1.4.1. Dearth of awareness and required infrastructural facilities
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Pharmacogenomics Market, by Technology
- 6.1. Introduction
- 6.2. DNA Sequencing
- 6.3. Electrophoresis
- 6.4. Mass Spectrometry
- 6.5. Microarray
- 6.6. Polymerase Chain Reaction
- 7. Pharmacogenomics Market, by Application
- 7.1. Introduction
- 7.2. Drug Discovery
- 7.3. Neurology
- 7.4. Oncology
- 7.5. Pain Management
- 8. Americas Pharmacogenomics Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Pharmacogenomics Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Pharmacogenomics Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Admera Health
- 12.1.2. Agena Biosciences Inc.
- 12.1.3. BiogeniQ Inc.
- 12.1.4. CENTOGENE N.V.
- 12.1.5. Coriell Life Sciences
- 12.1.6. Dynamic DNA Laboratorie
- 12.1.7. Empire Genomics
- 12.1.8. Illunima Inc.
- 12.1.9. Myriad Genetics Inc.
- 12.1.10. OneOme LLC
- 12.1.11. Personalis Inc.
- 12.1.12. Phamatech Inc.
- 12.1.13. Quest Diagnostics
- 12.1.14. Thermo Fisher Scientific Inc.
- 12.1.15. ViennaLab Diagnostics GmbH
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. PHARMACOGENOMICS MARKET RESEARCH PROCESS
- FIGURE 2. PHARMACOGENOMICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. PHARMACOGENOMICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. PHARMACOGENOMICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. PHARMACOGENOMICS MARKET DYNAMICS
- FIGURE 7. PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
- FIGURE 8. PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 10. PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.